ZURICH, Oct 14 (Reuters) - Roche (ROG.VX) reported a 3 percent drop in third-quarter sales, as top-selling cancer drug Avastin faced one of its toughest periods, failing to give the Swiss company the boost it needed after a series of setbacks.
ZURICH, Oct 14 (Reuters) - Roche (ROG.VX) reported a 3 percent drop in third-quarter sales, as top-selling cancer drug Avastin faced one of its toughest periods, failing to give the Swiss company the boost it needed after a series of setbacks.
